[1] SMYTH EC, NILSSON M, GRABSCH HI, et al. Gastric cancer[J]. Lancet, 2020, 396(10251): 635. doi: 10.1016/S0140-6736(20)31288-5
[2] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394. doi: 10.3322/caac.21492
[3] LV YJ, WANG W, JI CS, et al. Association between periostin and epithelial‐mesenchymal transition in esophageal squamous cell carcinoma and its clinical significance[J]. Oncol Lett, 2017, 14(1): 376. doi: 10.3892/ol.2017.6124
[4] SCHWANEKAMP JA, LORTS A, VAGNOZZI RJ, et al. Deletion of periostin protects against atherosclerosis in mice by altering inflammation and extracellular matrix remodeling[J]. Arterioscler Thromb Vasc Biol, 2016, 36(1): 60. doi: 10.1161/ATVBAHA.115.306397
[5] SUN B, GUO W, HU S, et al. Gprc5a-knockout mouse lung epithelial cells predicts ceruloplasmin, lipocalin 2 and periostin as potential biomarkers at early stages of lung tumorigenesis[J]. Oncotarget, 2017, 8(8): 13532. doi: 10.18632/oncotarget.14589
[6] DU B, SHIM JS. Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer[J]. Molecules, 2016, 21(7): 965. doi: 10.3390/molecules21070965
[7] FATTAHI S, AMJADI-MOHEB F, TABARIPOUR R, et al. PI3K/AKT/mTOR signaling in gastric cancer: Epigenetics and beyond[J]. Life Sci, 2020, 262: 118513. doi: 10.1016/j.lfs.2020.118513
[8] GONZÁLEZ-GONZÁLEZ L, ALONSO J. Periostin: A matricellular protein with multiple functions in cancer development and progression[J]. Front Oncol, 2018, 8: 225. doi: 10.3389/fonc.2018.00225
[9] NUZZO PV, BUZZATTI G, RICCI F, et al. Periostin: a novel prognostic and therapeutic target for genitourinary cancer?[J]. Clin Genitourin Cancer, 2014, 12(5): 301. doi: 10.1016/j.clgc.2014.02.005
[10] SUAREZ-CARMONA M, LESAGE J, CATALDO D, et al. EMT and inflammation: inseparable actors of cancer progression[J]. Mol Oncol, 2017, 11(7): 805. doi: 10.1002/1878-0261.12095
[11] CHO ES, KANG HE, KIM NH, et al. Therapeutic implications of cancer epithelial-mesenchymal transition (EMT)[J]. Arch Pharm Res, 2019, 42(1): 14. doi: 10.1007/s12272-018-01108-7
[12] WANG L, OUYANG F, LIU X, et al. Overexpressed CISD2 has prognostic value in human gastric cancer and promotes gastric cancer cell proliferation and tumorigenesis via AKT signaling pathway[J]. Oncotarget, 2016, 7(4): 3791. doi: 10.18632/oncotarget.6302